Literature DB >> 23830839

Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines.

A D'cruz1, T Lin2, A K Anand3, D Atmakusuma4, M J Calaguas5, I Chitapanarux6, B C Cho7, B C Goh8, Y Guo9, W S Hsieh10, C Hu9, D Kwong11, J C Lin12, P J Lou13, T Lu2, K Prabhash1, V Sriuranpong14, P Tang15, V V Vu16, I Wahid17, K K Ang18, A T Chan19.   

Abstract

Head and neck cancer (HNC) is a disease of the upper aerodigestive tract and is one of the most frequently diagnosed cancers worldwide. A high rate of cancers involving the head and neck are reported across the Asian region, with notable variations between countries. Disease prognosis is largely dependent on tumor stage and site. Patients with early stage disease have a 60-95% chance of cure with local therapy. Early diagnosis and appropriate treatment are important to increase the likelihood of cure and survival. However, the majority of patients present with locally advanced disease and require multimodality treatment. This necessitates, a multidisciplinary approach which is essential to make appropriate treatment decisions, particularly with regards to tolerability, costs, available infrastructure and quality of life issues. Unfortunately, majority of the studies that dictate current practice have been developed in the west where diseases biology, patient population and available infrastructure are very different from those in the Asian continent. With this in mind an expert panel of Head and Neck Oncologists was convened in May 2012 to review the National Comprehensive Cancer Network (NCCN) and the European Society for Medical Oncology (ESMO) clinical practice guidelines and develop practical recommendations on the applicability of these guidelines on the management of head and neck cancer for Asian patients. The objective of this review and consensus meeting was to suggest revisions, to account for potential differences in demographics and resources, to the NCCN and ESMO guidelines, to better reflect current clinical management of head and neck cancer within the Asian region for health care providers. These recommendations, which reflect best clinical practice within Asia, are expected to benefit practitioners when making decisions regarding optimal treatment strategies for their patients.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Asia; Guidelines; Head and neck cancer

Mesh:

Year:  2013        PMID: 23830839     DOI: 10.1016/j.oraloncology.2013.05.010

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  21 in total

Review 1.  Does East meet West? Towards a unified vision of the management of Nasopharyngeal carcinoma.

Authors:  Elaine Johanna Limkin; Pierre Blanchard
Journal:  Br J Radiol       Date:  2019-05-31       Impact factor: 3.039

2.  Comparison of different guidelines for oral cancer.

Authors:  Hugo Fontan Köhler; Hisham Mehanna; Jatin P Shah; Alvaro Sanabria; Johannes Fagan; Moni A Kuriakose; C Rene Leemans; Brian O'Sullivan; Suren Krishnan; Luiz P Kowalski
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-10-15       Impact factor: 2.503

3.  In vitro assessment of the role of DpC in the treatment of head and neck squamous cell carcinoma.

Authors:  Ye-Xing Xu; Man-Li Zeng; Di Yu; Jie Ren; Fen Li; Anyuan Zheng; Yong-Ping Wang; Chen Chen; Ze-Zhang Tao
Journal:  Oncol Lett       Date:  2018-03-15       Impact factor: 2.967

4.  Perception and attitudes versus medical writing skills.

Authors:  P M Parikh
Journal:  South Asian J Cancer       Date:  2015 Apr-Jun

5.  Definitive Chemoradiotherapy Versus Surgery Followed by Adjuvant Radiotherapy in Resectable Stage III/IV Hypopharyngeal Cancer.

Authors:  Jun Won Kim; Mi Sun Kim; Se-Heon Kim; Joo Hang Kim; Chang Geol Lee; Gwi Eon Kim; Ki Chang Keum
Journal:  Cancer Res Treat       Date:  2015-03-13       Impact factor: 4.679

6.  Oncology Gold Standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck.

Authors:  Govind Babu; Ankur Bahl; G S Bhattacharya; K T Bhowmik; P S Dattatraya; Nikhil Ghadyalpatil; S M Karandikar; Padmaj Kulkarni; Nithya Sridharan; Purvish Parikh; Kumar Prabhash; T Raja; S Rajasundaram; S Subramanian; Kaustav Talapatra; Ashok Vaid
Journal:  South Asian J Cancer       Date:  2017 Oct-Dec

7.  Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.

Authors:  Junlin Yi; Xiaodong Huang; Zhengang Xu; Shaoyan Liu; Xiaolei Wang; Xiaohui He; Dehong Luo; Jingwei Luo; Jianping Xiao; Shiping Zhang; Kai Wang; Yuan Qu; Yuan Tang; Weixin Liu; Guozhen Xu; Li Gao; Dian Wang
Journal:  Oncotarget       Date:  2017-07-04

8.  Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.

Authors:  Makoto Tahara; Kei Muro; Yasuhisa Hasegawa; Hyun Cheol Chung; Chia-Chi Lin; Bhumsuk Keam; Kenichi Takahashi; Jonathan D Cheng; Yung-Jue Bang
Journal:  Cancer Sci       Date:  2018-02-08       Impact factor: 6.716

9.  Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.

Authors:  Yan-Ye Su; Chih-Yen Chien; Sheng-Dean Luo; Tai-Lin Huang; Wei-Che Lin; Fu-Min Fang; Tai-Jan Chiu; Yen-Hao Chen; Chi-Chih Lai; Cheng-Ming Hsu; Shau-Hsuan Li
Journal:  World J Surg Oncol       Date:  2016-03-22       Impact factor: 2.754

10.  Osteopontin Involves Cisplatin Resistance and Poor Prognosis in Oral Squamous Cell Carcinoma.

Authors:  Sheng-Dean Luo; Yi-Ju Chen; Chien-Ting Liu; Kun-Ming Rau; Yi-Ching Chen; Hsin-Ting Tsai; Chang-Han Chen; Tai-Jan Chiu
Journal:  Biomed Res Int       Date:  2015-09-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.